Figure 6.

Antitumour efficacy of OCT4 and BIRC5 co-suppression in mouse xenograft models. (A) Hep3B cells were injected into BALB/c (nu/nu) mice for establishing xenograft tumours. Adenoviruses carrying Dual-shRNA, BIRC5-shRNA, OCT4-shRNA were used to treat tumours by intratumoural injections with a total dosage of 109 pfu viruses per mouse, and the tumour volume was measured every week. (B) Observation was ended (day 39 after treatment) when the tumours were over 2,500 mm3. Mice were killed, tumours were removed and weighed; *, P < 0.05, n = 5; **, P < 0.01, n = 5. (C) The paraffin-embedded consecutive sections of tumours were detected for OCT4 and BIRC5 expression by immunohistochemistry and for counting apoptotic cells by TUNEL, original magnification 200 × .

Cao et al. BMC Cancer 2013 13:82   doi:10.1186/1471-2407-13-82
Download authors' original image